Market capitalization | $3.76m |
Enterprise Value | $-10.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.40 |
EV/Sales (TTM) EV/Sales | -4.92 |
P/S ratio (TTM) P/S ratio | 1.74 |
P/B ratio (TTM) P/B ratio | 0.41 |
Revenue growth (TTM) Revenue growth | 227.92% |
Revenue (TTM) Revenue | $2.16m |
As a Free StocksGuide user, you can view scores for all 6,906 stocks worldwide.
2 Analysts have issued a Oncternal Therapeutics Inc forecast:
2 Analysts have issued a Oncternal Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2.16 2.16 |
227%
227%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -36 -36 |
18%
18%
|
EBIT (Operating Income) EBIT | -36 -36 |
18%
18%
|
Net Profit | -35 -35 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focuses on drug development of untapped biological pathways implicated in cancer progression. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.
Head office | United States |
CEO | James Breitmeyer |
Employees | 27 |
Founded | 1997 |
Website | www.oncternal.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.